Balance Sheet
Cash Flow Statement
Beginning Cash BalanceBeginning Cash BalanceCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationDepreciation ExpenseEBIATLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingWages, Salaries and Other
Ratios

Calidi Biotherapeutics (CLDI) Short-Term Debt repayments (2023)

Calidi Biotherapeutics' quarterly Short-Term Debt repayments came in at $400000.0 in Q2 2023, down 75.0% quarter-over-quarter from $1.6 million in Q1 2023.

Calidi Biotherapeutics has reported Short-Term Debt repayments for 1 years, with the latest figure at $400000.0 in Q2 2023.

  • For the quarter ending Q2 2023, Short-Term Debt repayments changed N/A year-over-year to $400000.0; the trailing twelve-month figure through Dec 2023 stood at $2.0 million (changed N/A YoY), and the FY2023 full-year result was $2.0 million, up 100.0% from the prior year.
  • Short-Term Debt repayments for Q2 2023 stood at $400000.0, down from $1.6 million in the prior quarter.
  • The five-year high for Short-Term Debt repayments was $1.6 million in Q1 2023, with the low at $400000.0 in Q2 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Short-Term Debt repayments (Qtr)
1 Quantum Biopharma 1,638,563.89 Bn 1,638,563.89 Bn - -
2 Alterity Therapeutics 767,934.24 Bn 767,934.20 Bn - -
3 Legend Biotech 2,937.00 Bn 2,936.10 Bn 242.10 Mn -
4 Nanobiotix 2,282.79 Bn 2,282.72 Bn - -
5 Akari Therapeutics 2,169.69 Bn 2,169.69 Bn - 102,000.00
6 Vertex Pharmaceuticals 110.41 Bn 103.16 Bn 2.59 Bn -
7 Regeneron Pharmaceuticals 66.44 Bn 57.69 Bn 3.31 Bn -
8 Evaxion A 65.44 Bn 65.42 Bn - -
9 Alnylam Pharmaceuticals 39.53 Bn 36.52 Bn 959.66 Mn -
10 Calidi Biotherapeutics - - - -

Historic Data

Download Data 🔒
DateValue
Jun 30, 2023 400,000.00
Jun 30, 2023 400,000.00
Mar 31, 2023 1.60 Mn
Mar 31, 2023 1.60 Mn